Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. (9th February 2016)

• Record Type: Journal Article
• Authors: Maurer, Christian; Pflug, Natali; Bahlo, Jasmin; Kluth, Sandra; Rhein, Christina; Cramer, Paula; Gross‐Ophoff, Carolin; Langerbeins, Petra; Fink, Anna‐Maria; Eichhorst, Barbara; Kreuzer, Karl‐Anton; Fischer, Norbert; Tausch, Eugen; Stilgenbauer, Stephan; Böttcher, Sebastian; Döhner, Hartmut; Kneba, Michael; Dreyling, Martin; Binder, Mascha; Hallek, Michael; Wendtner, Clemens‐Martin; Bergmann, Manuela; Fischer, Kirsten
• Is Part Of: European journal of haematology. Volume 97:Number 3(2016:Sep.)
• Page Start: 253
• Page End: 260
• Publication Date: 2016-02-09
• Subjects: combination treatment with lenalidomide -- dose levels -- dose limiting toxicity -- overall response rate -- toxicity; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12714
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Purpose: A phase I/II trial to assess safety and efficacy of the combination bendamustine, rituximab, and lenalidomide (BRL) in patients with chronic lymphocytic leukemia (CLL). Patients and Methods: Seventeen relapsed or refractory (R/R) and five previously untreated (FL) CLL patients were enrolled in the trial. In the R/R cohort, four different dose levels of lenalidomide (maximum 15 mg/d) were used. In the FL cohort, lenalidomide was dose escalated from 5 mg/d to 15 mg/d. Bendamustine was used at doses of 50 or 90 mg/m 2 for R/R or FL treatment, respectively. 375 mg/m 2 Rituximab were used for the first and 500 mg/m 2 for subsequent treatment courses. Treatment consisted of up to six courses of 28 d. Results: The maximal tolerable dose of lenalidomide was 5 mg/d. The response rate was 47.1% in R/R and 60% in FL patients. Median progression‐free survival was 8.0 months. Median overall survival was 22.9 and 12.3 months, respectively, in R/R and FL patients. Grade 3/4 hematological toxicity was observed in 71.4%, and severe infections in 47.6% of patients. Due to high toxicity and low response rate of BRL, the trial was closed prematurely. Conclusion: BRL was associated with a high toxicity rate, a high number of treatment interruptions, and a low remission rate. Therefore, BRL cannot be considered an appropriate treatment option for patients with CLL.